Largest Opioid Review: Small Relief, Fast Dependence
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Sydney researchers led the largest review ever conducted on opioids for acute pain, synthesizing 59 systematic reviews covering more than 50 acute pain conditions in children and adults, published in the journal Drugs.
- Lead author Associate Professor Christina Abdel Shaheed said opioids did not provide large or lasting pain relief compared with placebo for the vast majority of acute pain conditions, with pain relief typically lasting only a few hours.
- The review found oral opioids were only slightly better than placebo for acute musculoskeletal pain in the 6 to 48 hours after starting treatment, while increasing the risk of side effects including nausea and vomiting.
- Opioids showed no advantage over placebo for several common scenarios, including some types of limb surgery, kidney stone pain, pain after tonsil removal, and pain in newborns on assisted breathing devices.
- The analysis identified modest, short-term benefit for stomach pain, dental surgery, ear procedures, traumatic limb injuries, childbirth, caesarean delivery, and bunionectomy, while finding inconsistent benefits for heart-related pain, post-hysterectomy pain, and topical opioid patches.
- Co-first author Dr. Stephanie Mathieson warned that persistent opioid use can develop quickly following first-time use — sometimes within days — even when taken for acute pain, not just chronic conditions.
- The researchers noted that many clinical trials inadequately reported side effects, suggesting the true risks of opioid use may be greater than currently documented in the evidence base.
Why it matters: By challenging the 'go-to' status of opioids across more than 50 acute pain conditions, the review gives prescribers, patients, and regulators a single evidence base to justify lower doses and shorter courses. The finding that dependence can begin within days of first use, combined with the researchers' warning that trial side-effect data is likely underreported, raises the stakes for every short-term prescription written today.
Ask SkimNews
